Fluticasone and vilanterol formulation and inhaler

Abstract

A composition comprising particulate fluticasone or a pharmaceutically acceptable salt or solvate thereof, particulate vilanterol trifenatate, at least one of 1,1,1,2,3,3,3-heptafluoropropane and 1,1,1,2-tetrafluoroethane.

1 . A composition comprising:
 particulate fluticasone or a pharmaceutically acceptable salt or solvate thereof;   particulate vilanterol trifenatate; and   at least one of 1,1,1,2,3,3,3-heptafluoropropane and 1,1,1,2-tetrafluoroethane.   
     
     
         2 . The composition of  claim 1 , wherein the fluticasone or a pharmaceutically acceptable salt or solvate thereof is fluticasone furoate. 
     
     
         3 . (canceled) 
     
     
         4 . The composition of  claim 1 , wherein the propellant consists essentially of 1,1,1,2,3,3,3-heptafluoropropane. 
     
     
         5 . The composition of  claim 1  contained in a canister, wherein the size of the fluticasone particles in the canister is between about 2 micrometers and 4 micrometers. 
     
     
         6 . The composition of  claim 1  contained in a canister, wherein the size of the vilanterol trifenatate particles in the canister is between about 1 micrometer and 2 micrometers. 
     
     
         7 - 9 . (canceled) 
     
     
         10 . A composition comprising
 particulate fluticasone or a pharmaceutically acceptable salt or solvate thereof;   particulate vilanterol or a pharmaceutically acceptable salt or solvate thereof; and   at least one of 1,1,1,2,3,3,3-heptafluoropropane and 1,1,1,2-tetrafluoroethane, wherein fluticasone and vilanterol or the pharmaceutically acceptable salts or solvates thereof are the only active medicaments in the composition.   
     
     
         11 . The composition of  claim 10 , wherein the fluticasone or a pharmaceutically acceptable salt or solvate thereof is fluticasone furoate. 
     
     
         12 . (canceled) 
     
     
         13 . The composition of  claim 10 , wherein the propellant consists essentially of 1,1,1,2,3,3,3-heptafluoropropane. 
     
     
         14 . The composition of  claim 10  contained in a canister, wherein the size of the fluticasone particles in the canister is between about 2 micrometers and 4 micrometers. 
     
     
         15 . The composition of  claim 10  contained in a canister, wherein the size of the vilanterol trifenatate particles in the canister is between about 1 micrometer and 2 micrometers. 
     
     
         16 . (canceled) 
     
     
         19 . The composition of  claim 10 , further comprising ethanol. 
     
     
         20 . An aerosol canister comprising a composition of  claim 1 . 
     
     
         21 . The aerosol canister of  claim 20  comprising at least one surface having a primer composition comprising a silane having two or more reactive silane groups separated by an organic linker group disposed thereon, wherein the primer composition has a coating composition comprising an at least partially fluorinated compound disposed thereon. 
     
     
         22 . (canceled) 
     
     
         23 . The aerosol canister of  claim 21 , wherein the at least one surface is at least a portion of a valve surface. 
     
     
         24 . An inhaler comprising the composition of  claim 1 . 
     
     
         25 . An aerosol canister comprising a composition of  claim 10 . 
     
     
         26 . The aerosol canister of  claim 25  comprising at least one surface having a primer composition comprising a silane having two or more reactive silane groups separated by an organic linker group disposed thereon, wherein the primer composition has a coating composition comprising an at least partially fluorinated compound disposed thereon. 
     
     
         27 . The aerosol canister of  claim 26 , wherein the at least partially fluorinated compound is a polyfluoropolyether silane. 
     
     
         28 . An inhaler comprising the composition of  claim 10 . 
     
     
         29 . An inhaler comprising the aerosol canister of  claim 20 .